New data shows Ocrevus Achieves Major Milestone in Reducing MS Disability Risk
Genentech’s latest announcement reveals groundbreaking results from their advanced PPMS study, highlighting the effectiveness of Ocrevus in reducing multiple sclerosis (MS) disability risk by 30%.